Table.

Clinical trials of NK cell immune checkpoint blockade with available research findings

	National clinical trial no.	Disease	Drugs	Phase	Status
NKG2A	NCT03341936	Squamous cell carcinoma of the head and neck	Nivolumab; lirilumab	II	Active, not recruiting
	NCT04307329	Breast cancer	Monalizumab; trastuzumab	II	Completed
	NCT04590963	Squamous cell carcinoma of the head and neck	Monalizumab; cetuximab	III	Active, not recruiting
	NCT03822351	Stage III non-small cell lung cancer	Durvalumab; oleclumab; monalizumab	II	Completed
	NCT02671435	Advanced solid tumors	Monalizumab; durvalumab; cetuximab	I/II	Active, not recruiting
	NCT02557516	Chronic lymphocytic leukemia	Monalizumab	I/II	Terminated
PD-1	NCT04927884	Advanced triple negative breast cancer	Sacituzumab	I/II	Terminated
	NCT02660034	Solid tumors	Tislelizumab; pamiparib	I	Completed
	NCT03532451	Bladder cancer	Nivolumab; lirilumab	I	Completed
	NCT03241927	Melanoma	Pembrolizumab	II	Terminated
TIGIT	NCT03563716	Non-small cell lung cancer	Atezolizumab; tiragolumab	II	Active, not recruiting
TIM-3	NCT02608268	Advanced malignancies	Sabatolimab; spartalizumab; 5-aza-2′-deoxycytidine	I/II	Terminated
	NCT03489343	Metastatic cancer	Sym023	I	Completed
	NCT04812548	Myelodysplastic syndrome	Sabatolimab; azacitidine; venetoclax	II	Terminated
KIR	NCT03341936	Squamous cell carcinoma of the head and neck	Nivolumab; lirilumab	II	Active, not recruiting
	NCT03347123	Solid tumors	Epacadostat; nivolumab; ipilimumab; lirilumab	I/II	Terminated
	NCT01592370	Hematologic malignancies	Nivolumab; ipilimumab; lirilumab	I/II	Completed
	NCT02399917	Myeloid leukemia	Azacitidine; lirilumab	II	Terminated
	NCT00552396	Multiple myeloma	1- 7 F9	I	Completed
	NCT01222286	Smoldering multiple myeloma	IPH 2101	II	Completed
	NCT01248455	Multiple myeloma	IPH 2101	II	Terminated
	NCT00999830	Multiple myeloma	IPH 2101	II	Completed
	NCT01687387	Acute myeloid leukemia	IPH 2102	II	Completed
	NCT02481297	Chronic lymphocytic leukemia	Lirilumab; rituximab	II	Completed
LAG-3	NCT02996110	Advanced cancer	Nivolumab; ipilimumab; relatlimab	II	Completed
	NCT02750514	Advanced cancer	Nivolumab; dasatinib; relatlimab	II	Terminated
	NCT02935634	Advanced gastric cancer	Nivolumab; ipilimumab; relatlimab	II	Completed
	NCT03489369	Lymphoma	Sym 022	I	Completed
	NCT03493932	Glioblastoma	Nivolumab; BMS-986016	I	Completed
	NCT03470922	Melanoma	Relatlimab; nivolumab	II/III	Active, not recruiting
	NCT03724968	Metastatic melanoma	Nivolumab; ipilimumab; relatlimab	II	Terminated
KIR+PD-1+CTLA-4	NCT01714739	Solid tumor	Lirilumab; nivolumab; ipilimumab	I/II	Completed
PD-1+TIGIT	NCT04952597	Limited stage small cell lung cancer	Ociperlimab; tislelizumab; pemetrexed	II	Completed
PD-1+LAG-3	NCT02061761	Hematologic neoplasms	Relatlimab; nivolumab	I/II	Completed
PD-1+LAG-3	NCT04634825	Head and neck cancer	Enoblituzumab; retifanlimab; tebotelimab	II	Terminated
PD-1+LAG-3	NCT03484923	Melanoma	PDR001; LAG525; INC280	II	Completed
PD-1+LAG-3	NCT03662659	Gastric cancer	Nivolumab; relatlimab	II	Completed
PD-1+LAG-3	NCT03365791	Small cell lung cancer	PDR001; LAG525	II	Completed
PD-1+LAG-3	NCT03250832	Neoplasms	TSR-033; dostarlimab; mFOLFOX6;	I	Completed
PD-1+CTLA-4+LAG-3	NCT02488759	Various advanced cancer	Nivolumab; ipilimumab; relatlimab; daratumumab	I/II	Completed

NKG2A, natural killer group 2 member A; PD-1, programmed death-1; TIGIT, T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains; TIM-3, T cell immunoglobulin and mucin-domain containing-3; KIR, killer cell immunoglobulin-like receptor; LAG-3, lymphocyte activation gene-3; CTLA-4, cytotoxic T lymphocyte antigen-4